Please login to the form below

Not currently logged in
Email:
Password:

Entyvio

This page shows the latest Entyvio news and features for those working in and with pharma, biotech and healthcare.

Takeda offers €520m for stem cell firm TiGenix

Takeda offers €520m for stem cell firm TiGenix

Takeda is already a player in inflammatory bowel diseases with its Entyvio (vedolizumab) product for ulcerative colitis and Crohn’s disease, one of its key growth products.

Latest news

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA ... The best example is Entyvio. It

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics